# Erenumab for Idiosyncratic Facial Pain

> **NCT04249427** · PHASE4 · COMPLETED · sponsor: **David Jang, M.D.** · enrollment: 29 (actual)

## Conditions studied

- Facial Pain
- Rhinosinusitis

## Interventions

- **DRUG:** Erenumab Prefilled Syringe
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04249427
- **Lead sponsor:** David Jang, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-10
- **Primary completion:** 2023-07-11
- **Final completion:** 2023-07-11
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249427, "Erenumab for Idiosyncratic Facial Pain". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04249427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*